Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Limited as of April 24, 2025. This change in shareholding, involving multiple transactions of ordinary shares controlled by Morgan Stanley, could impact the company’s market dynamics and investor relations, reflecting a shift in stakeholder interests.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, providing pathology services across Australia. The company focuses on delivering high-quality diagnostic services to medical practitioners and patients, contributing to the healthcare sector’s efficiency and effectiveness.
YTD Price Performance: -13.24%
Average Trading Volume: 978,993
Technical Sentiment Signal: Buy
Current Market Cap: A$581.8M
See more data about ACL stock on TipRanks’ Stock Analysis page.